Clincosm LogoSign in Get a demo

Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and to Compare Safety, Effect on Quality of Life, and Resource Utilization of Injectafer vs Intravenous Standard of Care for the Treatment of IDA in an Infusion Center Setting

Sponsor
American Regent, Inc. (Industry)
Overall Status
Unknown status
CT.gov ID
NCT01950247
Collaborator
(none)
1,000
Enrollment
2
Arms
49.5
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The main objective of this study is to compare the safety, effect on quality of life, and resource utilization of Injectafer vs. intravenous (IV) iron standard of care (SOC) for the treatment of iron deficiency anemia (IDA) in an infusion center setting. The study will also assess the ability of baseline serum hepcidin levels to predict if subjects will have a clinically meaningful hemoglobin response to oral iron therapy or to IV iron therapy.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

The main objective of this study is to compare the safety, effect on quality of life, and resource utilization of Injectafer vs. intravenous (IV) iron standard of care (SOC) for the treatment of iron deficiency anemia (IDA) in an infusion center setting. The study will also assess the ability of baseline serum hepcidin levels to predict if subjects will have a clinically meaningful hemoglobin response to oral iron therapy for 28 days or to IV iron therapy.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1000 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life, and Resource Utilization of Injectafer vs. Intravenous Iron Standard of Care for the Treatment of Iron Deficiency Anemia (IDA) in an Infusion Center Setting
Actual Study Start Date :
Aug 15, 2013
Actual Primary Completion Date :
Oct 20, 2016
Anticipated Study Completion Date :
Oct 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Injectafer

2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.

Drug: Injectafer
2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
Other Names:
  • Ferric Carboxymaltose (FCM)

    		•
    Active Comparator: IV Iron Standard of Care (SOC)

    At a dose and administration regimen as determined by the study site investigator

    Drug: SOC
    Other Names:
  • IV Iron Standard of Care

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Change from baseline to Day 30 for Short Form Health Survey, 12-Item SF-12v2 quality of life scores [Day 30]

    2. Change from baseline to Day 30 for Multidimensional Assessment of Fatigue (MAF) scores [Day 30]

    3. Change from baseline to Day 30 for Work Productivity and Activity Impairment Questionnaire (WPAI) scores [Day 30]

    4. Treatment Satisfaction Questionnaire for Medication (TSQM) scores on Day 30 [Day 30]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Male or female subjects ≥ 18 years of age and able to give informed consent.

    • Iron deficiency is the primary etiology of anemia.

    • If using erythropoiesis stimulating agent (ESA), the subject must be using a dose consistent with package insert that has been stable for at least 30 days.

    • Doses of potential myelosuppressive medications have been stable for at least 30 days.

    • Females at risk of pregnancy must agree to use an acceptable form of birth control and have a negative serum or urine pregnancy test on the first day of dosing.

    Exclusion Criteria:

    • Hypersensitivity reaction to any component of Injectafer.

    • Requires dialysis for treatment of chronic kidney disease (CKD).

    • No evidence of iron deficiency.

    • During the 10 day period prior to screening has been treated with intravenous iron.

    • During the 30 day period prior to screening has been treated with a red red blood cell transfusion.

    • Any non-viral infection.

    • Known positive hepatitis with evidence of active disease.

    • Received an investigational drug within 30 days of screening.

    • Alcohol or drug abuse within the past 6 months.

    • Hemochromatosis or other iron storage disorders.

    • Estimated life expectancy of less than 6 months, or for cancer patients, an ECOG Performance Status greater than 1.

    • Pregnant or actively trying to become pregnant (a definitive negative result on a serum or urine pregnancy test performed on the first day of dosing will be required for study enrollment by any women of childbearing potential).

    • Any other laboratory abnormality, medical condition or psychiatric disorders which in the opinion of the investigator would put the subject's disease management at risk or may result in the subject being unable to comply with study requirements.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • American Regent, Inc.

    Investigators

    • Study Director: Sumita Chowdhury, MD, American Regent, Inc.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    American Regent, Inc.
    ClinicalTrials.gov Identifier:
    NCT01950247
    Other Study ID Numbers:
    • 1VIT13032
    First Posted:
    Sep 25, 2013
    Last Update Posted:
    Sep 8, 2017
    Last Verified:
    Sep 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Additional relevant MeSH terms:
    Anemia
    Anemia, Iron-Deficiency

    Study Results

    No Results Posted as of Sep 8, 2017